These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 20143654)

  • 1. Maintenance of remission with low-dose omalizumab in long-lasting, refractory chronic urticaria.
    Romano C; Sellitto A; De Fanis U; Esposito G; Arbo P; Giunta R; Lucivero G
    Ann Allergy Asthma Immunol; 2010 Jan; 104(1):95-7. PubMed ID: 20143654
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of omalizumab on patients with chronic urticaria.
    Spector SL; Tan RA
    Ann Allergy Asthma Immunol; 2007 Aug; 99(2):190-3. PubMed ID: 17718108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omalizumab also successful in chronic urticaria.
    Spector SL; Tan RA
    J Allergy Clin Immunol; 2008 Mar; 121(3):784; author reply 784-5. PubMed ID: 18328900
    [No Abstract]   [Full Text] [Related]  

  • 4. Monitoring omalizumab treatment efficacy in chronic urticaria by the basophil activation test.
    Rodríguez-Trabado A; Fernández Pereira LM; Romero-Chala S; García-Trujillo JA; Cámara Hijón C
    Allergol Immunopathol (Madr); 2012; 40(6):390-2. PubMed ID: 22178123
    [No Abstract]   [Full Text] [Related]  

  • 5. Omalizumab--an effective and safe treatment of therapy-resistant chronic spontaneous urticaria.
    Groffik A; Mitzel-Kaoukhov H; Magerl M; Maurer M; Staubach P
    Allergy; 2011 Feb; 66(2):303-5. PubMed ID: 21208221
    [No Abstract]   [Full Text] [Related]  

  • 6. Omalizumab is effective in nonautoimmune urticaria.
    Ferrer M; Gamboa P; Sanz ML; Goikoetxea MJ; Cabrera-Freitag P; Javaloyes G; Berroa F; Kaplan AP
    J Allergy Clin Immunol; 2011 May; 127(5):1300-2. PubMed ID: 21315432
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria.
    Song CH; Stern S; Giruparajah M; Berlin N; Sussman GL
    Ann Allergy Asthma Immunol; 2013 Feb; 110(2):113-7. PubMed ID: 23352531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab.
    Magerl M; Staubach P; Altrichter S; Ardelean E; Krause K; Metz M; Weller K; Maurer M
    J Allergy Clin Immunol; 2010 Sep; 126(3):665-6. PubMed ID: 20673981
    [No Abstract]   [Full Text] [Related]  

  • 9. A retrospective review of clinical presentation, thyroid autoimmunity, laboratory characteristics, and therapies used in patients with chronic idiopathic urticaria.
    Najib U; Bajwa ZH; Ostro MG; Sheikh J
    Ann Allergy Asthma Immunol; 2009 Dec; 103(6):496-501. PubMed ID: 20084843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy of omalizumab in seven patients with treatment-resistant chronic spontaneous urticaria.
    Silva PM; Costa AC; Mendes A; Barbosa MP
    Allergol Immunopathol (Madr); 2015; 43(2):168-73. PubMed ID: 24731771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic alternatives for chronic urticaria: additional reports on omalizumab.
    Spector SL; Tan RA
    Ann Allergy Asthma Immunol; 2008 Dec; 101(6):647. PubMed ID: 19119713
    [No Abstract]   [Full Text] [Related]  

  • 12. Two cases of severe refractory chronic idiopathic urticaria treated with omalizumab.
    Vestergaard C; Deleuran M
    Acta Derm Venereol; 2010 Jul; 90(4):443-4. PubMed ID: 20574627
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of omalizumab on patients with chronic urticaria: issues with the determination of autoimmune urticaria.
    Sheikh J
    Ann Allergy Asthma Immunol; 2008 Jan; 100(1):88; author reply 88-9. PubMed ID: 18254490
    [No Abstract]   [Full Text] [Related]  

  • 14. Partial improvement of solar urticaria after omalizumab.
    Waibel KH; Reese DA; Hamilton RG; Devillez RL
    J Allergy Clin Immunol; 2010 Feb; 125(2):490-1. PubMed ID: 20159260
    [No Abstract]   [Full Text] [Related]  

  • 15. D-dimer: a biomarker for antihistamine-resistant chronic urticaria.
    Asero R
    J Allergy Clin Immunol; 2013 Oct; 132(4):983-6. PubMed ID: 23763979
    [No Abstract]   [Full Text] [Related]  

  • 16. Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy.
    Corren J; Shapiro G; Reimann J; Deniz Y; Wong D; Adelman D; Togias A
    J Allergy Clin Immunol; 2008 Feb; 121(2):506-11. PubMed ID: 18269927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omalizumab as a therapeutic alternative for chronic urticaria.
    Callejas-Rubio JL; Sánchez-Cano D; Lara MA; Ortego-Centeno N
    Ann Allergy Asthma Immunol; 2008 Nov; 101(5):556. PubMed ID: 19055216
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy.
    Metz M; Bergmann P; Zuberbier T; Maurer M
    Allergy; 2008 Feb; 63(2):247-9. PubMed ID: 18186820
    [No Abstract]   [Full Text] [Related]  

  • 19. IgE levels are negatively correlated with clinical response to ciclosporin in chronic spontaneous urticaria.
    Santiago L; Ferreira B; Ramos L; Gonçalo M
    Br J Dermatol; 2019 Jan; 180(1):199-200. PubMed ID: 30007073
    [No Abstract]   [Full Text] [Related]  

  • 20. Plasma histamine but not anaphylatoxin levels correlate with generalized urticaria from infusions of anti-lymphocyte monoclonal antibodies.
    Dykewicz MS; Rosen ST; O'Connell MM; Patterson R; Kuzel TM; Gilyon KA
    J Lab Clin Med; 1992 Aug; 120(2):290-6. PubMed ID: 1500827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.